Abstract:Cyclooxygenase-2 (COX-2) and ERK-MAPK mitogenic signaling pathways are important in human hepatocellular carcinoma. We investigated the effect of COX-2 inhibition on ERK-MAPK signaling and the effect of combining MEK (MAPK kinase) and COX-2 inhibitors in human hepatocellular carcinoma in vitro. COX and ERK expression were determined by immunoblot in HepG2 and Hep3B cells. COX-2 and MEK activity were determined by prostaglandin E(2) assay and phosphospecific immunoblot, respectively. Cell growth was determined by cell proliferation and cell counts. Apoptosis was determined by DNA fragmentation enzyme-linked immunosorbent assay and flow cytometry. Cell cycle was determined by flow cytometry. HepG2 and Hep3B cells do not express COX-1 or COX-2. Correspondingly, basal and agonist (arachidonic acid, lipopolysaccharide)-stimulated COX-2 activity is undetectable. Treatment of HepG2 and Hep3B cells with NS398 resulted in an increase in ERK1/2 phosphorylation (MEK activity) in a concentration-dependent fashion (NS398, 1 to 100 micromol/L). Treatment with the COX-2 inhibitor NS398 in the presence of U0126 (MEK inhibitor) effectively suppressed ERK1/2 phosphorylation as determined by phosphospecific ERK1/2 immunoblot. Total ERK1/2 and COX-2 were unchanged with NS398 and U0126 treatments. In HepG2 cells, NS398 (1 to 100 micromol/L) decreased apoptosis as determined by DNA fragmentation enzyme-linked immunosorbent assay. Relative apoptosis was increased with U0126 alone or in combination with NS398 (9 to 10 times the control value), eliminating the anti-apoptotic effect of NS398. In Hep3B cells, apoptosis was unchanged with NS398 (1 to 50 micromol/L) or U0126 (1 to 10 micromol/L) alone. The combination of NS398 and U0126 in Hep3B cells resulted in a synergistic increase in apoptosis (10 times the control value). Relative apoptosis in both cell lines strongly correlated with changes in the expression of the antiapoptotic protein Bcl-xL. Cellular growth was assessed by colorimetric proliferation assay and cell counts. HepG2 and Hep3B cells had concentration-dependent inhibition of cell growth with NS398 or U0126 treatment alone. The combination of NS398 and U0126 resulted in complementary inhibitory effects on growth. Growth inhibitory effects in HepG2 and Hep3B cells with combination treatment appear to be, in part, secondary to the induction of G(0)/G(1) and G(2)/M cell cycle arrest, respectively, as determined by flow cytometry. Despite differential signaling in HepG2 and Hep3B cells, the sum effect of combining the COX-2 inhibitor NS398 and the MEK inhibitor U0126 results in enhanced antitumor actions. This novel combination may be useful for in vivo studies of hepatocellular carcinoma.

Combination of Octreotide with Specific Cyclooxygenase-2 Inhibitor Enhances the Inhibitory Effect on Growth of Human Hepatocellular Carcinoma

Octreotide Inhibits Proliferation and Induces Apoptosis of Hepatocellular Carcinoma Cells.

Octreotide Inhibits Proliferation and Invasion of MHCC97-H Cells in Vitro and in Vivo

Effects of NS398, an inhibitor of cyclooxygenase 2, on the growth and apoptosis of human squamous cell carcinoma cell line Tca8113

Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

STUDY ON THE EXPRESSION OF CYCLOOXYGENASE-2 IN HEPATOCELLULAR CARCINOMA CELL LINES AND ON THE GROWTH INHIBITION EFFECT OF NS-398

In Vitro Enhancement of Radiation-Induced Apoptosis in Human Hepatoma Cell Line HepG2 by a Selective Inhibitor of Cyclooxygenase-2 Enzyme NS -398

Specific COX-2 Inhibitor NS398 Induces Apoptosis in Human Liver Cancer Cell Line HepG2 Through BCL-2

Effect of Octreotide on human hepatocellular cancer cell line MHCC97-H in vitro

Anti-carcinoma Effect of Targeted Radiotherapy Using 90Y-Dota-octreotide Mediated by Somatostatin Receptor

Octreotide Acts As an Antitumor Angiogenesis Compound and Suppresses Tumor Growth in Nude Mice Bearing Human Hepatocellular Carcinoma Xenografts.

Effect of Octreotide on Angiogenesis Induced by Hepatocellular Carcinoma in Vivo

Synergistic inhibition effects of gemcitabine and octreotide on prostate cancer cell line PC-3

The Effect of Octreotide on Proliferation and P-glycoprotein Expresslon of SGC-7901 Cell Line

Influence of Octreotide Combined with Fluorodeoxyuridine or Cisplatin on Fas and FasL Expression of SMMC-7721 Hepatic Cancer Cells

Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment

[NS398 Induced Apoptosis in Pancreatic Carcinoma Cell Strain BxPC-3 Through a COX-2-in Dependent Pathway].

Effect of tanshinone ⅡA on COX-2 expression in hepatocellular carcinoma cell line SMMC-7721

Effect of Taxotere Combination with Celecoxib on Proliferation of NSCLC Cell